Clinical Trial Update: A Study of BMN 255 in Participants With Non-Alcoholic Fatty Liver Disease And Hyperoxaluria [Phase 1]

View source ↗

Summary

BioMarin's BMN-255 Phase 1 trial in hyperoxaluria with nonalcoholic fatty liver disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperoxaluria
• Nephrolithiasis
• Nonalcoholic Fatty Liver Disease

Drugs mentioned

• BMN-255 (BMN-255)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Hyperoxaluria, Nonalcoholic Fatty Liver Disease | Phase 1 | Status: WITHDRAWN